TCGA-75-6207-01A-11R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- MYC_TARGETS_V1+0.450
- UNFOLDED_PROTEIN_RESPONSE+0.330
- OXIDATIVE_PHOSPHORYLATION+0.300
- DNA_REPAIR+0.290
- INTERFERON_ALPHA_RESPONSE+0.290
- ADIPOGENESIS+0.240
- E2F_TARGETS+0.240
- PROTEIN_SECRETION+0.240
- PEROXISOME+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- PANCREAS_BETA_CELLS-0.460
- KRAS_SIGNALING_DN-0.410
- HEDGEHOG_SIGNALING-0.370
- APICAL_SURFACE-0.330
- MYOGENESIS-0.320
- COAGULATION-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- CHOLESTEROL_HOMEOSTASIS-0.270
- ALLOGRAFT_REJECTION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650201 | — | — | 0.900 |
| 2 | R128 | — | — | 0.853 |
| 3 | MNG33 | — | — | 0.843 |
| 4 | 7AE107A7-8EA7-4920-A579-2337C007920D | — | — | 0.835 |
| 5 | MNG449 | — | — | 0.835 |
| 6 | R143 | — | — | 0.828 |
| 7 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.824 |
| 8 | BS_QXKRN6CR | Supratentorial Ependymoma | — | 0.818 |
| 9 | GSM5359428 | — | — | 0.811 |
| 10 | BS_QXKRN6CR | EPN | Supratentorial EPN | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |